TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8723170
Drug: Cilazapril 5
Normalized name: cilazapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 5 mg daily (n = 9)
Study: 8723170
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg daily (n = 8)
Study: 3892993
Drug: ALB (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALB (80 g albumin on the day of operation and 20 g for the following 3 days)
Study: 21715107
Drug: memantine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: memantine 15 mg bid
Study: 21715107
Drug: memantine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: memantine 30 mg bid
Study: 19564368
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg gemifloxacin as an oral tablet without probenecid
Study: 19564368
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg gemifloxacin as an oral tablet with 4.5 g probenecid divided in eight oral doses
Study: 3300408
Drug: nalbuphine 10
Normalized name: nalbuphine 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 10 mg
Study: 3300408
Drug: nalbuphine 20
Normalized name: nalbuphine 20 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 20 mg
Study: 3555569
Drug: pethidine 100
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pethidine 100 mg
Study: 29045207
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of tofacitinib administered orally twice daily
Study: 29045207
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of tofacitinib administered orally twice daily
Study: 29045207
Drug: Placebo (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (with a switch to 5 mg of tofacitinib at 3 months)
Study: 22990950
Drug: Multimodal shoulder
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal shoulder injection
Study: 21899843
Drug: Atorvastatin or
Normalized name: atorvastatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin or pitavastatin treatment
Study: 16481597
Drug: Creatine 10
Normalized name: creatine 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine 10 g/day
Study: 12762352
Drug: Chlorine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorine inhalation (1.0 parts per million for 15 min)
Study: 8151150
Drug: Aciclovir granules
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aciclovir granules (40% w/w aciclovir) at a dose of 20 mg/kg four times daily for five to seven days
Study: 8151150
Drug: Conventional symptomatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional symptomatic therapy
Study: 31916648
Drug: quadruple‐therapy with
Approvals — FDA: no, EMA: no, PMDA: no
Description: quadruple‐therapy with 2 g/day N. sativa
Study: 31916648
Drug: quadruple‐therapy with
Approvals — FDA: no, EMA: no, PMDA: no
Description: quadruple‐therapy with 2 g/day placebo
Study: 30173153
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) with Methotrexate (MTX) 20 mg/week
Study: 30173153
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) with Methotrexate (MTX) 7.5 mg/week
Study: 23368897
Drug: Fluticasone/formoterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol combination therapy (100/10 μg b.i.d. or 250/10 μg b.i.d.)
Study: 23368897
Drug: Fluticasone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone + formoterol (100 μg + 12 μg b.i.d. or 250 μg + 12 μg b.i.d.)
Study: 23368897
Drug: Fluticasone/formoterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol combination therapy
Study: 11323554
Drug: Creatine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (20 g.d‐1 for 5 days)
Study: 9195406
Drug: Interferon-alpha therapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha therapy (6-9 MU; six times weekly for 2 weeks followed by thrice weekly for 22 additional weeks)
Study: 8186869
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (20 Gy in four 5 Gy fractions)
Study: 8186869
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (20 Gy) plus local microwave hyperthermia
Study: 8186869
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with hyperthermia
Study: 25523718
Drug: High-dose trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose trivalent inactivated influenza vaccine (TIV) - 60 μg
Study: 25523718
Drug: Standard-dose trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose trivalent inactivated influenza vaccine (TIV) - 15 μg
Study: 14982697
Drug: Mecamylamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (10 mg oral)
Study: 11420874
Drug: Daily hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hemodialysis (DHD = 6 x 2 h/week)
Study: 8073910
Drug: Thymoxamine (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoxamine (alpha adrenergic receptor antagonist)
Study: 8073910
Drug: Methoxamine (alpha-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxamine (alpha-1 adrenergic receptor agonist)
Study: 2673620
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (0.07 mg/kg/min)
Study: 2673620
Drug: Nicotine during
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine during adenosine infusion
Study: 2673620
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of nicotine and adenosine
Study: 17250777
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg imipramine
Study: 11210404
Drug: Azithromycin 1200
Normalized name: azithromycin 1200 MG per 30 ML Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1200 mg/day (changed to 600 mg/day) for Days 8 to 21 with zidovudine 100 mg, five times/day.
Study: 11210404
Drug: Azithromycin 1200
Normalized name: azithromycin 1200 MG per 30 ML Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1200 mg/day for Days 8 to 21 with dideoxyinosine 200 mg twice daily.
Study: 11210404
Drug: Placebo equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo equivalent to azithromycin for Days 8 to 21 with dideoxyinosine 200 mg twice daily.
Study: 1981014
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with estrogenic recruitment (low doses of diethylstilbesterol)
Study: 25304836
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose antibiotic regimen (n = 103)
Study: 25304836
Drug: Multidose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidose antibiotic regimen (n = 102)
Study: 25359150
Drug: Pateclizumab 360
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pateclizumab 360 mg
Study: 20413058
Drug: Once-daily ADPREM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily ADPREM
Study: 20413058
Drug: Twice-daily CRM
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily CRM
Study: 8621019
Drug: Vanadyl sulfate
Normalized name: Vanadyl Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanadyl sulfate (100 mg/day)
Study: 1591738
Drug: Nimodipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (40 mg)
Study: 6389273
Drug: Antacid group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid group A (7.5 ml, 103.5 mmol antacid/day)
Study: 6389273
Drug: Antacid group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid group B (15 ml, 207 mmol antacid/day)
Study: 6389273
Drug: Antacid group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid group C (30 ml, 414 mmol antacid/day)
Study: 6389273
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (15 ml)
Study: 23380429
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg meloxicam orodispersible tablet (ODT)
Study: 3777684
Drug: Catecholamine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Catecholamine infusion (dopamine or dobutamine, Group III, n = 17)
Study: 26925704
Drug: Sativex (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sativex (up to 108 mg THC/100 mg CBD)
Study: 26925704
Drug: Self-titrated doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-titrated doses of Sativex
Study: 24077196
Drug: Lateral parasagittal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral parasagittal interlaminar epidural steroid injection (PIL)
Study: 24077196
Drug: Midline interlaminar
Normalized name: amidoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midline interlaminar epidural steroid injection (MIL)
Study: 20509997
Drug: Adefovir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir (10 mg once daily for 48 weeks)
Study: 12682421
Drug: alpha-tocopherol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-tocopherol (400 IU dL-a-tocopherol daily)
Study: 9010746
Drug: Estradiol-releasing vaginal
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol-releasing vaginal ring (2 mg/3 months) and oral progestin for 7 days every month
Study: 9010746
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (50 micrograms/day) with a levonorgestrel-releasing IUD (20 micrograms/day)
Study: 1446959
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (R)
Study: 3792350
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide and 5 mg amiloride hydrochloride (combination therapy)
Study: 3792350
Drug: Diuretics (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (50 mg hydrochlorothiazide and 5 mg amiloride hydrochloride)
Study: 19249923
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (PCA) with fentanyl 0.5 microg/kg every 15 minutes (maximum 4 doses/hour)
Study: 19249923
Drug: PRN intravenous
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN intravenous fentanyl 25-50 microg every 30 minutes
Study: 16441618
Drug: Alginate gel
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate gel Flaminal (test)
Study: 16441618
Drug: Hydrocolloid gel
Normalized name: Band-Aid Hydro Seal Hydrocolloid Gel Bandages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid gel Intrasite (control)
Study: 10886120
Drug: GR205171 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR205171 25 mg i.v. + ondansetron 8 mg i.v.
Study: 10886120
Drug: Hyoscine hydrobromide
Normalized name: Hyoscine hydrobromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine hydrobromide 0.6 mg orally (positive control)
Study: 9082268
Drug: Warm anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm anesthetic solution (37 degrees C)
Study: 9082268
Drug: Cold anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold anesthetic solution (20 degrees C)
Study: 8452165
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily for 10 days
Study: 8452165
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg twice daily for 10 days
Study: 3512783
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without bleomycin
Study: 3512783
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy with immunotherapy (BCG, levamisole, or both)
Study: 3512783
Drug: Initial full-dose
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial full-dose therapy for patients aged 65 or older
Study: 3512783
Drug: Initial dose
Normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose reduction of 50% for patients aged 65 or older
Study: 27716478
Drug: Panitumumab 6
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 6 mg/kg once every 2 weeks
Study: 27716478
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m2 followed by 250 mg/m2 weekly)
Study: 21660669
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light (BWL) treatment for 30 min every morning during chemotherapy
Study: 21660669
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light (DRL) treatment for 30 min every morning during chemotherapy
Study: 12379063
Drug: Rifampin and
Normalized name: Rifampin and Isoniazid Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin and pyrazinamide daily for 2 months (n = 307)
Study: 12379063
Drug: Isoniazid daily
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid daily for 6 months (n = 282)
Study: 1850142
Drug: Flumazenil 200
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil 200 mg
Study: 1850142
Drug: Flumazenil 600
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil 600 mg
Study: 6130073
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of buspirone
Study: 6130073
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of diazepam
Study: 6130073
Drug: Alcohol (0.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.85 g/kg for men; 0.72 g/kg for women)
Study: 31420063
Drug: Featback (automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Featback (automated feedback on a short monitoring questionnaire weekly)
Study: 31420063
Drug: Featback with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Featback with weekly e‐mail or chat support from an expert patient
Study: 31420063
Drug: Weekly support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly support from an expert patient
Study: 23080350
Drug: Subfascial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subfascial injection of 30 mL of ropivacaine 0.5%
Study: 23080350
Drug: Extrafascial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafascial injection of 30 mL of ropivacaine 0.5%
Study: 16950429
Drug: Propionyl‐L‐carnitine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl‐L‐carnitine (6 g/day)
Study: 15568141
Drug: Ethanol 0.73
Normalized name: ethanol 0.73 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.73 g/kg, 1 h before isoniazid, followed by 0.11 g/kg ethanol orally every hour thereafter for 7 h
Study: 9209670
Drug: Intrapleural combination
Normalized name: INTRAPLEURAL MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural combination of DDP (60 mg/m2) and CBDCA (270 mg/m2)
Study: 9209670
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous DDP treatment
Study: 9209670
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of CBDCA alone
Study: 30293364
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with narrow-spectrum intense pulsed light and fractional carbon dioxide laser
Study: 24169248
Drug: LMA I-gel
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMA I-gel
Study: 21394052
Drug: 0.5‐mg ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐mg ranibizumab
Study: 21394052
Drug: 4‐mg triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐mg triamcinolone
Study: 18329580
Drug: Active low-level
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active low-level laser therapy (LLLT) (Helium Neon, 632.8 nm, 30 mW)
Study: 18329580
Drug: Sham low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham low-level laser therapy (placebo)
Study: 14747424
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral dose of imatinib (capsule)
Study: 14747424
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral dose of imatinib (oral solution)
Study: 14747424
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg i.v. infusion of imatinib
Study: 8283896
Drug: Algorithm therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm therapy based on on-site coagulation monitoring
Study: 2660970
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections for 1 year
Study: 5343357
Drug: L-DOPA (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA (high oral dosage)
Study: 24051437
Drug: ERAP (cell‐permeable
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERAP (cell‐permeable peptide inhibitor)
Study: 24051437
Drug: Tamoxifen (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (standard treatment)
Study: 21536689
Drug: Computer-assisted therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted therapies
Study: 21536689
Drug: Weaker comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weaker comparison conditions (e.g., wait-list controls)
Study: 15291859
Drug: Early and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early and high-dose epirubicin (360 mg, 12 instillations)
Study: 15291859
Drug: Delayed and
Normalized name: TABLET, DELAYED AND EXTENDED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed and high-dose epirubicin (360 mg, 12 instillations)
Study: 15291859
Drug: Delayed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Delayed low-dose epirubicin (180 mg, 30 mg once every 2 weeks, six times)
Study: 15291859
Drug: Early low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early low-dose epirubicin (180 mg, three instillations before 7 days after TURBT)
Study: 11256987
Drug: Inhaled terbutaline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline, 0.5 mg three times daily for 2 weeks
Study: 11256987
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, 400 microg twice daily for 2 weeks
Study: 9048145
Drug: Enhanced methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced methadone treatment
Study: 29196825
Drug: FORTA-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FORTA-guided treatment
Study: 29196825
Drug: Standard geriatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard geriatric treatment
Study: 11929419
Drug: Decongestants (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestants (topical or oral)
Study: 11929419
Drug: Unknown medication
Normalized name: Fe heme polypeptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unknown medication
Study: 1888325
Drug: Treatment effectiveness
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effectiveness
Study: 9466525
Drug: Investigational vaccines
Normalized name: INVESTIGATIONAL VACCINES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational vaccines (three types)
Study: 1803847
Drug: Active buffering
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active buffering lozenge (Profylin)
Study: 1803847
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge (not buffered)
Study: 1803847
Drug: Active buffering
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active buffering lozenge (Profylin) after sucrose rinse
Study: 1803847
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge after sucrose rinse
Study: 31119846
Drug: TRK‐100STP 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRK‐100STP 120 μg
Study: 28273240
Drug: Laser pan-retinal
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser pan-retinal photocoagulation with intravitreal bevacizumab injections
Study: 26649465
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioural therapy (ICBT) with therapist support for 10 weeks
Study: 12476542
Drug: Desloratadine/pseudoephedrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine/pseudoephedrine (5 mg/240 mg)
Study: 12476542
Drug: Pseudoephedrine (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine (240 mg)
Study: 9761434
Drug: UFT (Tegafur
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (Tegafur and Uracil) administered post-operatively to 98 patients
Study: 9761434
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no UFT administered to 557 patients)
Study: 7642053
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy (thrombolysis) for AMI